# Nebivolol and the Endothelin (ET)-1 System

> **NCT01395329** · PHASE4 · COMPLETED · sponsor: **University of Colorado, Boulder** · enrollment: 42 (actual)

## Conditions studied

- Prehypertension
- Hypertension

## Interventions

- **DRUG:** Nebivolol
- **DRUG:** Metoprolol
- **DRUG:** Placebo
- **OTHER:** Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
- **OTHER:** FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
- **OTHER:** FBF response to Acetylcholine
- **OTHER:** FBF response to Sodium Nitroprusside
- **OTHER:** FBF response to BQ-123+BQ-788+ACh

## Key facts

- **NCT ID:** NCT01395329
- **Lead sponsor:** University of Colorado, Boulder
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01395329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01395329, "Nebivolol and the Endothelin (ET)-1 System". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01395329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*